Aromatase Inhibitor Musculoskeletal Syndrome

Abstract Aromatase inhibitor (AI) musculoskeletal syndrome (AIMSS) is very common in women taking an AI as part of their breast cancer treatment. Although the exact cause of AIMSS is not clearly known, there is speculation that estrogen has an important role in the proper function of joints and the reduction in estrogen as part of this treatment can contribute to the development of joint symptomatology in users. The early identification and initiation of treatment can help reduce pain, minimize loss of function, and maximize quality of life. Physiatrists can have a very important role in the assessment and treatment of this disabling condition.